Atelerix funding news – England-based Atelerix Secures £750k in Funding

Transporting biological samples like cells, tissues, viruses, and blood products while maintaining their quality is a major challenge in healthcare. Reliable sample preservation is vital for drug discovery, accurate diagnoses, and clinical trials.

However, traditional cryopreservation methods often reduce cell viability by up to 50% after thawing and require expensive, specialized equipment. Additionally, complex cell models, tissues, and blood products cannot be frozen at all, leading to a costly, wasteful, and inflexible supply chain for fresh samples.

Read also - Wingbits Funding News- Sweden- based Wingbits Raises €5.3Mn to Transform Flight Tracking

It’s technology allows cells to be stored and transported at 4-25°C, avoiding the problems caused by freezing and thawing. It keeps cells over 90% viable for 14 days at room temperature, while cutting shipping costs by 50-80%. Unlike cryogenic methods, it uses standard packaging instead of costly containers and hazardous dry ice.

By simplifying logistics lowering costs, and preserving cell quality, Atelerix’s solution removes barriers in drug and cell therapy development, letting scientists focus on breakthrough treatments and better patient care.

Additionally, it eliminates the need for energy-hungry freezers, dry ice, and harmful refrigerants, reducing CO2 emissions by 99.7% per shipment.

Alastair Carrington, CEO of Atelerix, says, “Atelerix is transforming biological transport by eliminating the need for deep freezing, setting a sharp new standard that displaces traditional cryologistics. Through innovative partnerships with leading life science companies and strong customer validation, we are redefining how laboratories operate worldwide.”

ACF Investors and biotech-focused o2h Ventures participated in the funding round.

Sam Fennell, Partner at ACF Investors, highlighted Atelerix’s innovative platform, strong intellectual property and growing customer base as key factors positioning the company to meet the rising demand for sustainable logistics. He said, “We’re thrilled to support a team transforming a traditional industry and look forward to their next growth phase.”

Sunil Shah, CEO of o2h Ventures, first saw Atelerix pitch at Cambridge Angels and had their sister company, o2h Discovery, test the gel on real cells.

The investment will support Atelerix in boosting its branding and sales efforts, helping its hydrogels become the go-to solution for shipping biosamples.

About Atelerix

Atelerix offers a game-changing alternative to cryopreservation. Their gel doesn’t need freezing, making it easier to store and transport cells, tissues, and viruses without the hassle of traditional cold storage methods.